Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro.
AUTOR(ES)
Dale, G L
RESUMO
Several carriers were evaluated for use in the delivery of exogenous glucocerebrosidase to monocytes from Gaucher's disease patients. Only gamma globulin-coated, resealed erythrocytes proved to be an effective vehicle for enzyme delivery. Glucocerebrosidase added in this manner normalized intracellular enzyme levels for at least 18 hr. In this model system for the study of enzyme replacement therapy, soluble enzyme, enzyme in uncoated resealed erythrocytes, and enzyme incorporated into liposomes were ineffective.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=382963Documentos Relacionados
- The glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal enzyme.
- Enzyme replacement therapy in Gaucher's disease: a rapid, high-yield method for purification of glucocerebrosidase.
- Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration.
- Gaucher's disease in South Africa.
- Pericardial abnormalities in Gaucher's disease.
